

KURZPROTOKOLL
14V-MC-JAHN

Öffentlicher Titel	Phase III Studie zu Baricitinib bei atopischer Dermatitis
Wissenschaftl. Titel	A Phase 3 Multicenter, Double-Blind Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Adult Patients with Atopic Dermatitis
Kurztitel	14V-MC-JAHN
Studienart	multizentrisch, prospektiv, Therapiestudie, randomisiert, Pharma-Studie, doppelblind, mehrarmig
Studienphase	Phase III
Erkrankung	Haut: Ekzem (Dermatitis): Neurodermitis (Atopische Dermatitis)
Einschlusskriterien	<ul style="list-style-type: none">- Have completed the final active treatment visit for an originating study eligible to enroll participants directly into study BREEZE-AD3 OR- Meet criteria for NCT03334396 or NCT03334422
Ausschlusskriterien	<ul style="list-style-type: none">- Had investigational product permanently discontinued at any time during a previous baricitinib study- Had temporary investigational product interruption continue at the final study visit of a previous baricitinib study and, in the opinion of the investigator, this poses an unacceptable risk for the participant's participation in the study
Alter	18 Jahre und älter
Prüfzentren	Klinik für Dermatologie, Venerologie und Allergologie (Nachbeobachtung) Theodor-Stern-Kai 7 60590 Frankfurt am Main Dr. med. Andreas Pinter Tel: 069 6301-83115 Fax: 069 6301-83175 andreas.pinter@unimedizin-ffm.de
Sponsor	Eli Lilly and Company
Registrierung in anderen Studienregistern	ClinicalTrials.gov NCT03334435 (primäres Register) EudraCT 2017-000873-35